Kana Enomoto, Acting Administrator, Substance Abuse and Mental Health Services Administration, keynote presentation at the National Rx Drug Abuse & Heroin Summit March 29, 2016
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Drug Treatment Courts: How America’s Most Trusted Alternative to Incarceration is Providing Hope in the Midst of the Rx Drug Abuse and Opiate Epidemic - Vision Session Presented by National Association of Drug Court Professionals
April 3, 2017
The current opiate epidemic has spurred long-overdue scrutiny on the pharmaceutical production and distribution of opiate medication, but it also raises questions of public policy and law regarding the regulation of medical access to and use of opiate medications with high potential for addiction. Expert panelists will address the challenges that arise from efforts to balance restrictions on access to opiates to limit addiction while also preserving sufficient access for legitimate medical management of pain.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/opiate-regulation-policies
Drug Treatment Courts: How America’s Most Trusted Alternative to Incarceration is Providing Hope in the Midst of the Rx Drug Abuse and Opiate Epidemic - Vision Session Presented by National Association of Drug Court Professionals
April 3, 2017
The current opiate epidemic has spurred long-overdue scrutiny on the pharmaceutical production and distribution of opiate medication, but it also raises questions of public policy and law regarding the regulation of medical access to and use of opiate medications with high potential for addiction. Expert panelists will address the challenges that arise from efforts to balance restrictions on access to opiates to limit addiction while also preserving sufficient access for legitimate medical management of pain.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/opiate-regulation-policies
The Levamicoke campaign was initiated in late 2009 by members of Toronto’s Research Group on Drug Use. Our goal is to raise awareness about recent reports of Levamisole-laced cocaine and crack. The reason that we’re doing this is that Levamisole is turning up everywhere. It’s in the majority of cocaine and crack on the global market. It has serious health effects that are surfacing everywhere that cocaine and crack are being used. It may not be reported because it’s not a reportable illness, but this quietness is not a conspiracy, it’s just a fact of life.
This presentation demonstrates the failure of U.S. marijuana prohibition and supports calls for evidence-based models to legalize and regulate the use of cannabis. It provides an overview of the ICSDP's report "Tools for Debate" which can be found at http://www.icsdp.org/research/publications.aspx
SPECIAL ARTICLEFor editorialcomment, seepage 269From.docxwilliame8
SPECIAL ARTICLE
For editorial
comment, see
page 269
From the Department
Psychiatry & Psychology
(T.A.R.) and Departmen
Internal Medicine (M.C.
Mayo Clinic, Rochester
and Department of Inte
Medicine, Mayo Clinic,
sonville, FL (N.L.D.).
344
How Good Intentions Contributed to Bad
Outcomes: The Opioid Crisis
of
t of
B.),
, MN;
rnal
Jack-
Teresa A. Rummans, MD; M. Caroline Burton, MD; and Nancy L. Dawson, MD
Abstract
The opioid crisis that exists today developed over the past 30 years. The reasons for this are many. Good
intentions to improve pain and suffering led to increased prescribing of opioids, which contributed to
misuse of opioids and even death. Following the publication of a short letter to the editor in a major
medical journal declaring that those with chronic pain who received opioids rarely became addicted,
prescriber attitude toward opioid use changed. Opioids were no longer reserved for treatment of acute
pain or terminal pain conditions but now were used to treat any pain condition. Governing agencies began
to evaluate doctors and hospitals on their control of patients’ pain. Ultimately, reimbursement became tied
to patients’ perception of pain control. As a result, increasing amounts of opioids were prescribed, which
led to dependence. When this occurred, patients sought more in the form of opioid prescriptions from
providers or from illegal sources. Illegal, unregulated sources of opioids are now a factor in the increasing
death rate from opioid overdoses. Stopping the opioid crisis will require the engagement of all, including
health care providers, hospitals, the pharmaceutical industry, and federal and state government agencies.
ª 2017 Mayo Foundation for Medical Education and Research n Mayo Clin Proc. 2018;93(3):344-350
T
here is no debate that the United
States is in the midst of an opioid
crisis. Between 1999 and 2014, drug
overdose deaths nearly tripled.1 In 2016,
more than 60,000 people died from drug
overdoses, and opioids were responsible for
most of these deaths.2 For the first time since
1999, life expectancy decreased for US citizens
compared with citizens of other developed
countries, and opioid overdoses were a factor.3
This crisis includes both prescription and
nonprescription (illegal) use of opioid drugs.
Prescription opioids include natural and semi-
synthetic opioids such as codeine and
morphine, and synthetic opioids such as
methadone, fentanyl, and tramadol. Many of
the synthetic agents such as fentanyl are man-
ufactured and distributed illegally. With the
increased availability of both prescribed and
illegally obtained opioids over the past 30
years, there has been an increase in misuse
and deaths (Figure).4
Various opioids have been available for
more than a century, and opioid misuse has
occurred during that time. Following the Civil
War, veterans who suffered severe injuries
were given morphine for pain relief. In the
late 1800s, pharmaceutical companies began
Mayo Clin Proc. n March 201
www.m.
The world is watching as Canada becomes one of the first countries to legalize recreational cannabis, and there's still much we don't know about how this huge social change will affect our lives.
In this webinar, Dr. Chris Wilkes, MD, from UCalgary's Cumming School of Medicine reviews what the research to date tells us about the impact of cannabis on the brain, and what needs further study. Dr. Fiona Clement, PhD, whose team compiled the Cannabis evidence series for the Alberta provincial government, looks at the factors informing government policy, including evidence from other jurisdictions that have legalized marijuana.
Watch the full webinar recording at https://go.ucalgary.ca/2018-07-11URNAP-WhatdoeslegalizedcannabismeanforCanadians_LPRegistration.html
This research paper focuses on prescription opioids and its effects on the African American community. The author discusses the background, best treatment intervention, and ethical considerations associated with prescription opioids and their use within the African American population.
We are living through a psychedelic renaissance. Spearheaded by academic research and increasingly of interest to media, government and business, substances like psilocybin, LSD and MDMA are returning to our culture after a 40+ year hiatus.
So why all the excitement? How much of this is hype, and how much is potential for real positive impact?
This presentation is about ways psychedelics may be able to do a lot of good. It covers:
- Current efforts towards psychedelic mainstreaming (an overview of the landscape)
- The problems of trauma, depression, anxiety, and addiction, and how psychedelics can help
- How psychedelics might change our personality traits and values
- Long-termist arguments for why psychedelics could improve the future of human health, wellbeing, and flourishing
- What Aaron is working on in the psychedelic space
Learn more about Aaron here: https://anesmithbeck.com
---
First link in the presentation that doesn't work on SlideShare: https://psychedelic.support/resources/how-to-join-psychedelic-clinical-trial/
Some of the most hotly debated aspects of legalized marijuana centre around our youth. How does cannabis use affect adolescent brains? What do parents need to know, given the legal consumption ages established by provincial governments?
Experts from UCalgary’s Cumming School of Medicine examine the scientific evidence we have so far on cannabinoids and adolescent brain development, and who might be at most risk. Learn why a public health approach to legalized cannabis is vital, and get practical advice on navigating the new realities of mainstream marijuana.
Watch the full webinar recording at: https://go.ucalgary.ca/2018-07-26URCannabisandyouth_LPRegistration.html
A presentation by Brian D Sites at the 2017 meeting of the Scandinavian Society of Anaestesiology and Intensive Care Medicine.
All available content from SSAI2017: https://scanfoam.org/ssai2017/
Delivered in collaboration between scanFOAM, SSAI & SFAI.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
2. ADVANCING THE BEHAVIORAL HEALTH
OF THE NATION:
AMERICA’S OPIOID CRISIS
Kana Enomoto
Substance Abuse and Mental Health Services Administration
2016 National RX Drug Abuse & Heroin Summit
Atlanta, GA • March 29, 2016
5. 5
US death rates
fell steadily
until 1999
Case & Deaton. Rising morbidity
and mortality in midlife among white
Non-Hispanic Americans in the 21st
century. PNAS [epub Nov 2, 2015].
Sweden
Australia
Canada
UK
US
Hispanics
Germany
France
US non-Hispanic
Whites
… but then began
to increase
among middle-
aged white
Americans
Deathsper100,000population
ages45-54
OVERDOSE
9. 9
INCREASING USE OF NALOXONE
• NEW: SAMHSA
Prescription
Drug Overdose
Grants
• $12,000,000
• 10 States
• Purchase, Equip,
Train
10. 10
NEW: Buprenorphine
Notice of Proposed
Rulemaking
NEW: MAT Pocket
Guide
EXPANDING ACCESS TO MAT
•NEW: SAMHSA Medication Assisted Treatment for
Prescription Drug and Opioid Addiction (MAT-
PDOA) Grants
•$25,000,000
•23 States
•Focus on high-need communities
12. 12
Continuing education to over 72,000
primary care physicians, dentists,
and other healthcare professionals
31,552 physicians with a
waiver to prescribe
buprenorphine for opioid
dependence
Over 76,500 Downloads
OUR IMPACT
Baby Asa at 15 months old
Birth mom and dad continue to use heroin and multiple other substances including bath salts
Parental rights have been terminated
Small, but fierce Thriving and soon to be adopted